SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290293.
  • 2
    Konopka JB,Watanabe SM,Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984; 37: 10351042.
  • 3
    O'Brien SG,Guilhot F,Larson RA,Gathmann I,Baccarani M,Cervantes F,Cornelissen JJ,Fischer T,Hochhaus A,Hughes T, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 9941004.
  • 4
    Jabbour E,Kantarjian H,Jones D,Talpaz M,Bekele N,O'Brien S,Zhou X,Luthra R,Garcia-Manero G,Giles F, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20: 17671773.
  • 5
    Gadzicki D,von Neuhoff N,Steinemann D,Just M,Busche G,Kreipe H,Wilkens L,Schlegelberger B. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Cancer Genet Cytogenet 2005; 159: 164167.
  • 6
    Mahon FX,Belloc F,Lagarde V,Chollet C,Moreau-Gaudry F,Reiffers J,Goldman JM,Melo JV. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 23682373.
  • 7
    Illmer T,Schaich M,Platzbecker U,Freiberg-Richter J,Oelschlagel U,von Bonin M,Pursche S,Bergemann T,Ehninger G,Schleyer E. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401408.
  • 8
    Graham SM,Jorgensen HG,Allan E,Pearson C,Alcorn MJ,Richmond L,Holyoake TL. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319325.
  • 9
    Larghero J,Leguay T,Mourah S,Madelaine-Chambrin I,Taksin AL,Raffoux E,Bastie JN,Degos L,Berthaud P,Marolleau JP, et al. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem Pharmacol 2003; 66: 19071913.
  • 10
    Green H,Skoglund K,Rommel F,Mirghani RA,Lotfi K. CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: A pilot study on in vivo CYP3A activity. Eur J Clin Pharmacol 2010; 66: 383386.
  • 11
    Picard S,Titier K,Etienne G,Teilhet E,Ducint D,Bernard MA,Lassalle R,Marit G,Reiffers J,Begaud B, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 34963499.
  • 12
    Larson RA,Druker BJ,Guilhot F,O'Brien SG,Riviere GJ,Krahnke T,Gathmann I,Wang Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study. Blood 2008; 111: 40224028.
  • 13
    Thomas J,Wang L,Clark RE,Pirmohamed M. Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 2004; 104: 37393745.
  • 14
    White DL,Saunders VA,Dang P,Engler J,Venables A,Zrim S,Zannettino A,Lynch K,Manley PW,Hughes T. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 40644072.
  • 15
    White DL,Saunders VA,Dang P,Engler J,Zannettino AC,Cambareri AC,Quinn SR,Manley PW,Hughes TP. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697704.
  • 16
    Wang L,Giannoudis A,Lane S,Williamson P,Pirmohamed M,Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258264.
  • 17
    Holyoake T,Jiang X,Eaves C,Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94: 20562064.
  • 18
    Chomel JC,Bonnet ML,Sorel N,Bertrand A,Meunier MC,Fichelson S,Melkus M,Bennaceur-Griscelli A,Guilhot F,Turhan AG. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011; 118: 36573660.
  • 19
    Monici M. Cell and tissue autofluorescence research and diagnostic applications. Biotechnol Annu Rev 2005; 11: 227256.
  • 20
    Aubry JP,Blaecke A,Lecoanet-Henchoz S,Jeannin P,Herbault N,Caron G,Moine V,Bonnefoy JY. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry 1999; 37: 197204.
  • 21
    Steiger JH. Comparing correlations. In: Maydeu-Olivares A,McArdle JJ, editors. Contemporary Psychometrics: A Fetschrift in Honor of Roderick P. Mc Donald. Mahwah, NJ: Lawrence Erlbaum; 2004.
  • 22
    Cortes JE,Egorin MJ,Guilhot F,Molimard M,Mahon FX. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009; 23: 15371544.
  • 23
    Peng B,Hayes M,Resta D,Racine-Poon A,Druker BJ,Talpaz M,Sawyers CL,Rosamilia M,Ford J,Lloyd P, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935942.
  • 24
    Giannoudis A,Davies A,Lucas CM,Harris RJ,Pirmohamed M,Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): Implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008; 112: 33483354.
  • 25
    le Coutre P,Kreuzer KA,Pursche S,Bonin M,Leopold T,Baskaynak G,Dorken B,Ehninger G,Ottmann O,Jenke A, et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2004; 53: 313323.
  • 26
    Klawitter J,Kominsky DJ,Brown JL,Christians U,Leibfritz D,Melo JV,Eckhardt SG,Serkova NJ. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol 2009; 158: 588600.
  • 27
    Nambu T,Hamada A,Nakashima R,Yuki M,Kawaguchi T,Mitsuya H,Saito H. Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia. Biol Pharm Bull 2011; 34: 114119.
  • 28
    Mlejnek P,Novak O,Dolezel P. A non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite in Bcr-Abl positive cells. Talanta 2011; 83: 14661471.
  • 29
    Hatziieremia S,Jordanides NE,Holyoake TL,Mountford JC,Jorgensen HG. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Exp Hematol 2009; 37: 692700.
  • 30
    Racil Z,Razga F,Buresova L,Jurcek T,Dvorakova D,Zackova D,Timilsina S,Cetkovsky P,Mayer J. The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. Am J Hematol 2010; 85: 525528.
  • 31
    Bazeos A,Marin D,Reid AG,Gerrard G,Milojkovic D,May PC,de Lavallade H,Garland P,Rezvani K,Apperley JF, et al. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 2010; 24: 12431245.
  • 32
    Maffioli M,Camos M,Gaya A,Hernandez-Boluda JC,Alvarez-Larran A,Domingo A,Granell M,Guillem V,Vallansot R,Costa D, et al. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk Res 2011; 35: 10141019.
  • 33
    Apperley JF. Part 1: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 10181029.